PMCCPMCCPMCC

Search tips
Search criteria 

Advanced


 
Formats
Article sections
Authors
Logo of arthresbiomed central web sitesearch.manuscript submission.see also journal with issn 1478-6354registration.reference to the article.journal front page.
 
Arthritis Res. 2001; 3(Suppl A): P096.
Published online 2001 January 26. doi:  10.1186/ar265
PMCID: PMC3273227
Copyright ©2001 BioMed Central Ltd
Infiltrate analysis of rheumatoid synovial tissue before and after high does chemotherapy and autologous stem cell transplantation
RJ Verburg,1 R Flierman,1 EWN Levahrt,1 F van den Hoogen,2 FC Breedveld,1 and JM van Laar1
1Department of Rheumatology, Leiden University Medical Center
2Department of Rheumatology, University of Nijmegen, The Netherlands
Supplement
21st European Workshop for Rheumatology Research
Conference
21st European Workshop for Rheumatology Research
1-4 March 2001
Vienna, Austria
Received January 15, 2001
Objective
To investigate the effects of high dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) on the synovial infiltrate in rheumatoid arthritis.
Methods
8 patients with erosive, refractory, progressively rheumatoid arthritis, were treated with HDC (cyclophosphamide 200 mg/kg) and CD34 enriched selected ASCT. Biopsies of synovial tissue from a clinically involved knee were obtained by arthroscopy before and three months after HDC and ASCT. Immunohistochemistry was performed and blindly scored on a five point scale (0-4) using MoAbs specific for the following markers: CD3, CD4, CD8, CD25, CD27, CD45RA, CD45RO, CD45RB, CD19, CD20, CD22, CD38, CD5, CD68, HLA-DR, CD62L, CD62E, CD56 and CD55.
Results
There were no statistical significant differences (Wilcoxon's signed rank test) when the results before and after transplantation were compared. However when patients were divided in clinical responders (ACR > 50%, n = 5) and non-responders (ACR < 20%, n = 3) statistically significant differences with respect to several T-cell markers were found (Table).
Table 1
Table 1
Conclusions
There was a statistically significant difference (P < 0.05) between clinical responders and non-responders with respect to a decrease in infiltration of CD45RA+ and CD45RO+ cells after HDC and ASCT. CD27, CD45RO and CD45RB appear to be useful markers to predict clinical response.
Articles from Arthritis Research are provided here courtesy of
BioMed Central